Mizuho Maintains Outperform on ADMA Biologics, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Mizuho analyst Anthony Petrone maintains ADMA Biologics (NASDAQ:ADMA) with a Outperform and lowers the price target from $20 to $17.